The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
The closing price of Health Catalyst Inc (NASDAQ: HCAT) was $7.40 for the day, down -0.27% from the previous closing price of $7.42. In other words, the price has decreased by -$0.27 from its previous closing price. On the day, 0.61 million shares were traded. HCAT stock price reached its highest trading level at $7.65 during the session, while it also had its lowest trading level at $7.37.
Ratios:
Our analysis of HCAT’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 1.41 and its Current Ratio is at 1.41. In the meantime, Its Debt-to-Equity ratio is 1.03 whereas as Long-Term Debt/Eq ratio is at 0.37.
On January 03, 2024, Evercore ISI Upgraded its rating to Outperform which previously was In-line but kept the price unchanged to $11.
On January 03, 2024, Barclays started tracking the stock assigning a Overweight rating and target price of $14.Barclays initiated its Overweight rating on January 03, 2024, with a $14 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jan 06 ’25 when BENJAMIN LANDRY bought 2,500 shares for $7.42 per share.
DANIEL LESUEUR bought 5,209 shares of HCAT for $38,651 on Jan 06 ’25. On Dec 30 ’24, another insider, Gallagher Duncan, who serves as the Director of the company, sold 4,500 shares for $6.93 each. As a result, the insider received 31,184 and left with 69,938 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HCAT now has a Market Capitalization of 450272992 and an Enterprise Value of 427348672. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.51 while its Price-to-Book (P/B) ratio in mrq is 1.27. Its current Enterprise Value per Revenue stands at 1.415 whereas that against EBITDA is -13.321.
Stock Price History:
The Beta on a monthly basis for HCAT is 1.36, which has changed by -0.30263156 over the last 52 weeks, in comparison to a change of 0.24933672 over the same period for the S&P500. Over the past 52 weeks, HCAT has reached a high of $11.41, while it has fallen to a 52-week low of $5.42. The 50-Day Moving Average of the stock is -5.89%, while the 200-Day Moving Average is calculated to be 2.45%.
Shares Statistics:
HCAT traded an average of 513.35K shares per day over the past three months and 528390 shares per day over the past ten days. A total of 60.85M shares are outstanding, with a floating share count of 58.49M. Insiders hold about 3.89% of the company’s shares, while institutions hold 87.45% stake in the company. Shares short for HCAT as of 1734048000 were 2555695 with a Short Ratio of 4.98, compared to 1731628800 on 2530154. Therefore, it implies a Short% of Shares Outstanding of 2555695 and a Short% of Float of 4.279999999999999.
